|

Shanghai At Risk for Alzheimer's Disease: a Cohort Study

RECRUITINGSponsored by Ruijin Hospital
Actively Recruiting
SponsorRuijin Hospital
Started2022-03-01
Est. completion2029-03
Eligibility
Age50 Years+
Healthy vol.Accepted

Summary

The goal of this cohort study is to estimate the incidence of AD in the first-degree relatives of patients with AD. The main questions it aims to answer are: * cognitive changes of subjects at high risk of AD as ageing; * environmental and behavioral factors affecting AD incidence.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

1. the AD diagnostic criteria of probands meet the 2011 National Institute on Aging - Alzheimer's Association framework, and participants are the first-degree relatives (including parents, children and siblings of the same father and mother) of the proband;
2. not patients with dementia;
3. ≥ 50 years, males and females;
4. subjects have lived in Shanghai for more than 1 year and have no plan to move out of Shanghai within 5 years;
5. subjects are able to complete investigation, physical examination, imaging examination and biological specimen collection.

Exclusion criteria:

Individuals will be excluded if they have:

1. other diseases which could cause cognitive decline, e.g. cerebrovascular diseases, Creutzfeldt-Jakob disease and Parkinsons disease;
2. history of psychological disorders (according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition);
3. uncorrectable visual or auditory impairment that hampers the completion of related examination.
4. pre-menopausal women will also be excluded.

Conditions6

Alzheimer DiseaseAlzheimer's DiseaseCognitive ImpairmentDementiaNeurocognitive DisordersNeurodegenerative Diseases

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.